Profiel
Konrad Glund is the founder of Vivoryon Therapeutics NV, which was founded in 1997.
He held the title of Chief Executive Officer from 2006 to 2018.
Dr. Glund is also the founder of IFB Halle GmbH.
He previously worked as Vice President-Corporate Development at Prosidion Ltd.
and as a Principal at Martin-Luther-Universität Halle-Wittenberg.
Dr. Glund earned a doctorate degree from Martin-Luther-Universität Halle-Wittenberg.
Eerdere bekende functies van Konrad Glund
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Algemeen Directeur | 30-04-2018 |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
| IFB Halle GmbH | Algemeen Directeur | - |
Opleiding van Konrad Glund
| Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| IFB Halle GmbH | |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
